State of Oregon

University of California

Cytovia, Inc.

University of Oregon

Novalar Pharmaceuticals, Inc.

Cocensys Inc.

Orexigen Therapeutics, Inc.

Oregon Health & Science University

Nalpropion Pharmaceuticals LLC

Other

Warner-lambert Company

Acea Pharmaceuticals, Inc.

Euro-celtique S.a.

Cothera Bioscience, Inc.

Septodont Holding Sas

Eckard Weber

John F Keana

Sui Xiong Cai

John F W Keana

John A Drewe

Nancy C Lan

Gary Dennis Tollefson

Anthony A McKinney

Yan Wang

Christopher Franklin Bigge

Richard Woodward

Rick Soltero

Gordon B Mills

Michael Alexander Cowley

Douglas R Green

Howard Ian Katz

Sunil Kher

Andrew Xian Chen

Han-Zhong Zhang

Anthony P Guzikowski

Zhang-Lin Zhou

Peter Barmettler

Julius Knowles

Jonathan L Wright

Wu Yang

John Guastella

Po-wai Yuen

Richard Soltero

Thomas M Estok

John Fw Keana

Mark Sonders

Victor I Ilyin

Tracy Parrott

Craig E Jahr

Robin Lester

Tracy Lee Lawhon

Lufeng Guan

Andrew X Chen

Howard I Katz

Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.

Methods for administering weight loss medications

The present disclosure provides therapeutic methods of treating a cancer patient with TG02 and a second therapeutic agent, e.g., TG02 and an immune checkpoint inhibitor, TG02 and a COX-2 inhibitor, or TG02 and an immune checkpoint inhibitor and a COX-2 inhibitor.

Treatment of cancer with TG02

Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance &#x3b1;-MSH activity.

Compositions for affecting weight loss

In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.

Layered pharmaceutical formulations

The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.

Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof

The present invention relates to novel fluorescent dyes, novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of caspases and other enzymes involved in apoptosis in whole cells, cell lines and tissue samples derived from any living organism or organ. The reporter molecules and assay processes can be used in drug screening procedures to identify compounds which act as inhibitors or inducers of the caspase cascade in whole cells or tissues. The reagents and assays described herein are also useful for determining the chemosensitivity of human cancer cells to treatment with chemotherapeutic drugs. The present invention also relates to novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of type 2 methionine aminopeptidase, dipeptidyl peptidase IV, calpain, aminopeptidase, HIV protease, adenovirus protease, HSV-1 protease, HCMV protease and HCV protease.

Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof

Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.

Local anesthetic methods and kits

Growing community of inventors

Laguna Beach, CA, United States of America

Eckard Weber